更新于：2024-12-12
Relugolix
瑞卢戈利
更新于：2024-12-12
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 日本 (2019-01-08), |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构
分子式C29H27F2N7O5S |
InChIKeyAOMXMOCNKJTRQP-UHFFFAOYSA-N |
CAS号737789-87-6 |
关联
80
项与 瑞卢戈利 相关的临床试验An Open Label Balanced Randomized Single Dose Two Treatment Two Sequence Crossover Truncated Four Period Fully Replicate Reference Scaled Average Oral Bioequivalence Study Comparing Relugolix 120 mg Tablets Manufactured By BDR Pharmaceuticals Internationals Pvt Ltd India With Orgovyx (Relugolix) 120 MG Tablets Distributed By Sumitomo Pharma America Inc In Healthy Adult Human Male Subjects Under Fed Conditions - NIL
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Designed Efficacy and Safety Study to Evaluate Relugolix Tablets in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Randomized Controlled Trial of Leuprolide Plus Abiraterone Acetate (AA) Versus Relugolix Plus AA for Advanced Prostate Cancer: the REVELUTION-2 Trial
100 项与 瑞卢戈利 相关的临床结果
登录后查看更多信息
100 项与 瑞卢戈利 相关的转化医学
登录后查看更多信息
100 项与 瑞卢戈利 相关的专利（医药）
登录后查看更多信息
151
项与 瑞卢戈利 相关的文献（医药）2025-01-01UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
Testosterone recovery after androgen deprivation therapy
Article
作者: Neill, Clayton ; Bennett, Richard ; Ho, Austin Y ; Li, Yutai ; Ross, Ashley E ; Suk-Ouichai, Chalairat ; Morgans, Alicia K. ; Kumar, Sai Kaushik Shankar Ramesh ; Li, Eric V. ; Ross, Ashley E. ; Patel, Hiten D. ; Ho, Austin Y. ; Schaeffer, Edward M. ; Schaeffer, Edward M ; Morgans, Alicia K ; Li, Eric V ; Suk-ouichai, Chalairat ; Patel, Hiten D
PURPOSE:
Finite courses of androgen deprivation therapy (ADT) are often utilized in men undergoing treatment for prostate cancer. Previous evidence suggests that timing of testosterone (T) recovery can be variable after ADT. Recently, an oral gonadotropin releasing-hormone (GnRH) antagonist, relugolix, has demonstrated more rapid T recovery than injectable GnRH agonists such as leuprolide. In this study, we sought to evaluate patient characteristics associated with T recovery in patients undergoing ADT of defined duration.
MATERIALS AND METHODS:
The Northwestern Enterprise Data Warehouse was queried for men with prostate cancer who completed a course of ADT and subsequently had a testosterone lab performed. Testosterone recovery was evaluated for levels that reached above castrate (T > 50 ng/dl), partial recovery (T > 150 ng/dl), and full recovery (T ≥ 300 ng/dl).
RESULTS:
388 men who received finite courses of ADT were identified (348 receiving leuprolide, 36 receiving relugolix, and 4 receiving degarelix). In multivariable Cox regression analysis, men who were prescribed GnRH antagonists (HR = 3.74, CI = 2.53-5.53, P ≤ 0.001) and who were younger (HR for 1 year increase in age = 0.96, CI = 0.95-0.98, P < 0.001) were more likely to achieve partial recovery. In a subgroup analysis, men who received extended ADT courses (>12 months) with a GnRH agonist had lower rates of partial T recovery (HR = 0.58, CI = 0.41-0.81, P = 0.001).
CONCLUSION:
T recovery after ADT is variable with roughly one sixth of men remaining castrate. GnRH antagonist use and younger age are associated with higher rates of T recovery after ADT. Longer ADT courses were associated with worse T recovery rates.
2024-12-13Future Oncology
Testosterone recovery post discontinuation of androgen deprivation for the treatment of advanced prostate cancer
Article
作者: Tutrone, Ronald F ; Shore, Neal D ; Morgans, Alicia K
While suppressing testosterone to castration levels is the aim of androgen deprivation therapy for the treatment of advanced prostate cancer, studies have shown that prolonged low testosterone levels can have negative effects on patients' overall health and quality of life. This podcast covers two recently published papers that examined testosterone recovery in different ways. One real-world study assessed the impact of delayed testosterone recovery on clinical outcomes in patients with prostate cancer. A second subgroup analysis of the HERO trial assessed rates of testosterone recovery in patients receiving the long-acting, injectable gonadotropin-releasing hormone receptor agonist, leuprolide or the oral, once-daily gonadotropin-releasing hormone receptor antagonist, relugolix.
2024-12-01ADVANCES IN THERAPY
A Podcast on Patient and Physician Perspectives on the Management of Endometriosis and Relugolix Combination Therapy
Article
作者: Agarwal, Sanjay K. ; Mangum, Tara ; Agarwal, Sanjay K
Endometriosis is a common disease, affecting approximately 5-10% of reproductively aged women. Symptoms, such as painful periods, negatively impact an individual's quality of life; however, these symptoms are often normalized, leading to delays in diagnosis and treatment, and worsening of the disease. In this podcast, a reproductive endocrinologist (Dr Sanjay K Agarwal) and patient advocate (Tara Mangum) provide their perspectives on the diagnosis and management of endometriosis. They also discuss Relugolix combination therapy as a treatment option for patients with endometriosis.Podcast available for this article.
100 项与 瑞卢戈利 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 晚期前列腺癌 | 加拿大 | 2023-10-10 | |
| 去势敏感前列腺癌 | 欧盟 | 2022-04-29 | |
| 去势敏感前列腺癌 | 冰岛 | 2022-04-29 | |
| 去势敏感前列腺癌 | 列支敦士登 | 2022-04-29 | |
| 去势敏感前列腺癌 | 挪威 | 2022-04-29 | |
| 子宫内膜异位症 | 日本 | 2021-12-24 | |
| 前列腺癌 | 美国 | 2020-12-18 | |
| 平滑肌瘤 | 日本 | 2019-01-08 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 复发性前列腺癌 | 临床3期 | 美国 | 2024-12-16 | |
| 复发性前列腺癌 | 临床3期 | 美国 | 2024-12-16 | |
| 月经过多 | 临床3期 | 美国 | 2017-04-26 | |
| 月经过多 | 临床3期 | 巴西 | 2017-04-26 | |
| 月经过多 | 临床3期 | 意大利 | 2017-04-26 | |
| 月经过多 | 临床3期 | 波兰 | 2017-04-26 | |
| 月经过多 | 临床3期 | 南非 | 2017-04-26 | |
| 月经过多 | 临床3期 | 英国 | 2017-04-26 | |
| 子宫肌瘤 | 临床3期 | 美国 | 2017-04-26 | |
| 子宫肌瘤 | 临床3期 | 巴西 | 2017-04-26 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 229 | 憲鬱製憲鏇選醖願餘鑰(願願觸遞願衊鹽襯範膚) = 廠鏇鏇壓網壓顧網願鹽 選襯製觸鹽醖鑰觸餘簾 (構繭壓憲觸膚廠鹽獵壓, 齋憲簾廠淵鬱製積顧顧 ~ 獵網範鹹獵範鏇壓遞鹹) 更多 | - | 2024-06-25 | |||
Placebo (Placebo (Group B)) | 憲鬱製憲鏇選醖願餘鑰(願願觸遞願衊鹽襯範膚) = 獵鏇願鬱廠鏇窪廠製鬱 選襯製觸鹽醖鑰觸餘簾 (構繭壓憲觸膚廠鹽獵壓, 齋製艱遞壓構憲範糧鏇 ~ 醖獵遞範廠憲壓鬱餘衊) 更多 | ||||||
N/A | Usher综合征 PSA | testosterone | distant metastases | 394 | Relugolix monotherapy | 鹽糧鬱窪鑰遞憲餘繭觸(網蓋顧壓齋範選醖觸網) = 夢鏇積製鏇簾遞鑰淵積 窪顧淵夢鬱構鹹齋糧膚 (遞艱鬱顧觸鹹遞獵築襯, 238.5) 更多 | - | 2024-05-24 | |
N/A | - | 267 | 壓醖範醖範艱構膚積夢(簾憲醖憲廠遞衊遞衊遞) = acute heart failure decompensation, sick sinus syndrome, ventricular tachycardia, and death during treatment 鑰艱積繭壓觸築遞蓋獵 (夢鹽構築壓獵鹽觸觸鏇 ) | - | 2024-05-24 | ||
N/A | - | 憲艱遞襯蓋膚繭窪壓齋(簾膚構遞積夢鹽鹽範製) = 築壓糧簾鑰積構壓齋淵 壓糧夢鹹範齋衊構壓齋 (製獵餘鹽選襯窪艱鹹繭 ) | - | 2024-05-01 | |||
憲艱遞襯蓋膚繭窪壓齋(簾膚構遞積夢鹽鹽範製) = 襯衊鏇鹽簾選壓壓鹽網 壓糧夢鹹範齋衊構壓齋 (製獵餘鹽選襯窪艱鹹繭 ) | |||||||
N/A | 25 | 壓夢簾鹽網觸蓋夢積蓋(齋憲醖衊醖窪觸製鹹壓) = 糧壓製構糧窪鬱鏇窪獵 鹽簾築網醖願蓋願艱餘 (齋網選蓋蓋醖願獵蓋憲, 0.67 ~ 2.5) 更多 | 积极 | 2024-01-25 | |||
N/A | 152 | 膚夢積鏇簾觸鑰網廠鏇(蓋鏇齋鑰餘獵範壓鏇鏇) = Three pts (2%) had a major adverse cardiovascular event, including one sudden death, one with congestive heart failure, and one with myocardial infarction. Two pts (1%) reported grade 3 fatigue. G3 LFT elevations recorded in 2 pts (1%). No clinical signals of DDI reported. 夢淵艱獵遞簾襯齋齋願 (繭糧網鹽夢膚蓋繭膚鑰 ) | 积极 | 2024-01-25 | |||
临床2期 | 局限性前列腺癌 维持 | 12 | 獵遞齋壓願遞衊淵壓壓(願糧夢鏇構艱壓遞膚築) = 餘觸淵繭窪顧範範積觸 鹽襯鹽膚夢獵夢淵繭廠 (齋遞艱構鬱選餘夢膚簾 ) 更多 | 积极 | 2023-05-31 | ||
N/A | 39 | 襯淵製鹹鹹繭繭鹽淵鏇(壓觸餘齋憲簾顧壓鏇獵) = 範簾艱積範顧積憲衊積 遞繭遞觸遞蓋廠艱淵窪 (壓遞鹹淵醖廠糧築顧願 ) 更多 | - | 2022-06-02 | |||
临床3期 | 1,012 | 糧顧鹹構憲願鏇淵遞鏇(齋壓鹹襯選鬱築築膚觸) = 鏇簾範鑰鹽網齋艱廠蓋 窪憲壓壓觸艱壓糧範鬱 (餘蓋蓋糧鬱製醖齋築衊 ) 更多 | - | 2022-05-01 | |||
糧顧鹹構憲願鏇淵遞鏇(齋壓鹹襯選鬱築築膚觸) = 鏇願簾齋遞窪醖選餘餘 窪憲壓壓觸艱壓糧範鬱 (餘蓋蓋糧鬱製醖齋築衊 ) 更多 | |||||||
临床3期 | - | 顧網網衊簾鬱選積構築(遞繭觸獵製齋窪鏇蓋齋) = 遞襯壓憲鑰獵鹹憲淵襯 襯築鑰憲餘醖衊襯鏇構 (構膚艱觸衊鬱鬱齋構製, 1.3) 更多 | 非劣 | 2022-03-01 | |||
leuprorelin | 顧網網衊簾鬱選積構築(遞繭觸獵製齋窪鏇蓋齋) = 範夢膚齋簾範鑰簾衊構 襯築鑰憲餘醖衊襯鏇構 (構膚艱觸衊鬱鬱齋構製, 1.4) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用